US FDA Gave Green Signal To Tavalisse for the treatment of chronic immune thrombocytopenia (ITP)

U.S. FDA (Food and Drug Administration) extends its approval for Tavalisse (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP)

Company: Rigel Pharmaceutical Inc. 

Brand Name:  Tavalisse

Generic Name: fostamatinib

Dosage: Tablets 

Treatment For: Idiopathic (Immune) Thrombocytopenic Purpura

General information about Tavalisse

Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).